Norovirus is an Increasing Problem
Norovirus is a non-enveloped single strand RNA virus. One of the critical features of Norovirus is
infectivity. Infected individuals secrete
the virus in feces, saliva, and oral mucus.
Virus can be detectable in the saliva for up to 2 weeks after infection
even though most of the guidelines for food preparers suggests that they can go
back to work 2-3 days after the acute illness has passed. The infective dose for Norovirus is as little
as 18 viral particles (1). An infected person
is excreting billions of these particles. For comparison, influenza virus requires
a dose of about 1.95-3.0 x 103 infectious particles, and most common
respiratory viruses including SARS-CoV-2 are on par with Norovirus.
The clinical syndrome develops rapidly after exposure
resulting in abdominal cramping, vomiting and diarrhea. It creates significant mortality and morbidity
causing an estimated 213,000 deaths world-wide (2). In the US 900 people die per year out of 21
million infections. Most of the fatalities occur in the elderly and immunocompromised.
Rapid fluid loss and dehydration is most likely a causative factor especially in
the case of pre-existing medical problems. There is a bias toward advising all
people like they are healthy young adults and that this syndrome is a self-limited
2-3 day episode of stomach flu.
There is an asymptomatic carrier state with anywhere from 11.6-49.2%
of measured populations carrying the virus. This also extends to 1-3.4% of food
handlers. Humans were previously the
only known reservoir for this virus, but a recent review looked at modern data
and concluded that it may be a reverse zoonosis with human to animal
transmission in lab animals and the wild (3, 4).
Outbreaks of the virus are getting more common especially in
environments where there is close contact and contact with contaminated
surfaces like schools, universities, elderly homes, and cruise ships. In the US there are about 2,500 outbreaks per
year and poor granularity in terms of geographic locations. In other words,
unless a local news channel picks up the story of an outbreak – you probably
will not know until you get there. The
distribution of outbreaks over the calendar year for the last 4 years is given
at the top of this post. Outbreaks tend
to intensify in the winter months where there is more aggregation.
The most common advice given to prevent Norovirus infection
is hand washing and cleaning contaminated surfaces. The virus remains physically stable in pH 3-7
condition and temperatures up to 60 degrees C (140 degrees Fahrenheit) but that
conventional wisdom may not be enough.
The virus is aerosolized presumably by coughing, sneezing, and toilet
flushing and has been detected in the air around hospitalized patients (8). The
particles detected were in the droplet nuclei/aerosol range but that may be an artificial
dichotomy (9). The main point in this
research is that the droplets detected contained sufficient virus to cause
infection. Current CDC
precautions for Norovirus do not include masking except where there is a
risk of “splashes to the face during the care of patients, particularly among
those who are vomiting.” This is reminiscent
of the reluctance to declare respiratory viruses including SARS-CoV-2 and influenza
airborne.
6.6% of the US population are immunosuppressed based on taking immunosuppressant drugs or having a health condition that affects immunity and that number is increasing (10). Women are more likely to be affected than men. In addition to the immunocompromised - 39% of the population has at least one serious chronic illness any number of which can affect innate immunity (11). In addition, many of these diseases or their management can end up compromised by severe acute gastroenteritis. Common examples would be blood glucose management in diabetes mellitus and electrolyte and fluid management in hypertension, arrhythmias, and renal disease. Since 42% of the population has 2 or more chronic conditions it is highly likely that recommended management of rehydration will need to be personalized to that patient.
There are also nebulous recommendations about the quarantine
necessary following an episode of this illness.
The CDC web
site provides an example, in order:
“Most people with norovirus illness get better within 1
to 3 days; but they can still spread the virus for a few days after.”
“You can still spread norovirus for 2 weeks or more after
you feel better.”
“Stay home when sick for 2 days (48 hours) after symptoms
stop.”
Apparently, Norovirus has been detected in saliva for up to
2 weeks after infection – leading to this mixed recommendation. There is some additional
information at a public health link – but not much more. This link has
interesting information on clinical criteria without biological confirmation
that a probable Norovirus outbreak is occurring. In a 2013 review, Norovirus
was the second most common infection disease outbreak affecting psychiatric hospitals
(13). This review looks at infection
control procedures that may be unique to psychiatry as well as those that
address the difficult to destroy nature of the virus. It is resistant to common hand sanitizers and
the need for contact cleaning with hypochlorite while be masked and gowned to
prevent infection of staff. The
reference on the possible airborne nature of the virus also applies. A description
of a psychiatric hospital with 4 previous Norovirus outbreaks and how that was stopped
by a specific infection control program is also described (14).
That is currently the state-of-the-art on Norovirus. I have
some additional information posted below.
The best defense at this point is to know that this is a highly
infectious virus that is nothing to fool around with, especially if you are
elderly, have chronic medical conditions, or are immunocompromised. I don’t think it is my place to make specific
rehydration recommendations because of the complexity I describe in the above
paragraphs – but your personal physician certainly can. No matter what you read – avoiding dehydration
is the most important aspect. Your
physician can best describe how to do that given any other medical
conditions.
There are currently no vaccines or antiviral medications for
Norovirus. Vaccines are complicated by
several factors discussed in this paper (15) that projected vaccine availability
5-10 years out from 2014. Here we are 10
years out. Like the current SARS-CoV-2 vaccines early trials show a limited
duration of immunity, but that can eliminate many cases in more vulnerable
populations.
George Dawson, MD
Supplementary 1:
For 2025 – I decided to separate out my anecdotal experience
from the published scientific data. Readers of this blog know that my intent is
generally to include it as additional relevant information and I have joked
about trying to learn more about diseases by trying to get most of them. That is no different with Norovirus. The actual clinical syndrome I have seen many
times dating back to my days as a Peace Corps volunteer travelling in East
Africa. It was referred to as “Traveler’s
Diarrhea” and the theory was that it was caused by “enterotoxigenic E. Coli.” Various remedies were suggested including
Pepto Bismol (bismuth salicylate) or a prophylactic course of sulfamethoxazole/trimethoprim
(SMX/TMP) – an antibiotic that I subsequently prescribed many times as an
intern and resident.
All Peace Corps volunteers were issued a medical kit and the
two primary medications were a large bottle of Lomotil (diphenoxylate/atropine)
and another large bottle of Benadryl (diphenhydramine). So most acute diarrheal diseases were treated
with Lomotil. We also got IM cholera
vaccines that interestingly were discontinued shortly after my Peace Corps tour
because “they were more painful than protective.” The only currently approved cholera vaccine
is an oral vaccine.
My wife recently had a complicated course of appendicitis
and there was concern about the possibility of an intraabdominal abscess. As she recovered slowly from the surgery she
had residual right upper quadrant pain and suddenly developed an acute illness
again very similar to the appendicitis. I convinced her to go to free-standing emergency
department where she was treated for nausea and rapidly given 1 liter of normal
saline in less than 30 minutes. She was hypotensive and had a lot of vomiting and
diarrhea in the hours before this assessment.
A CT scan of the abdomen was negative and a PCR test of a stool sample
confirmed no C. difficile toxin and positive for Norovirus (see test panel
below).
Returning home she recovered over the next two days – but I contracted it and am recovering on day 3. I will post the symptom course in this note when I am fully recovered. I will note that my wife has had 2 episodes of SARS-CoV-2 infections in the past 3 years and I did not get them from the airborne route but was masked and using a UV air cleaner at the time. This time I was not masked – but I was using all of the CDC recommended contact precautions, the same UV air cleaner, and handwashing.
Supplementary 2:
Sometimes it pays to be a hoarder. I found this book in my auxiliary library today. It was sent to me by a friend who was attending Harvard Medical School when he heard I was definitely headed to Africa. I regaled my Peace Corps colleagues with tales of possible infections in Africa. The most interesting section for this post is that it provides an anchor point for diarrheal disease classification in 1975. It lists invasive and enteropathogenic E. coli as the primary pathogens detectable by culture and bioassay or an assay set up to detect the toxin. Epidemic viral gastroenteritis is attributed to Norwalk virus in the same book. The name originated from immune electron microscopy of a viral particle identified as a causative agent in Norwalk, Ohio. Episodic viral gastroenteritis at the time was attributed to rotavirus, duovirus, and orbivirus.
Supplementary 3:
References:
1: Winder N, Gohar S,
Muthana M. Norovirus: An Overview of Virology and Preventative Measures.
Viruses. 2022 Dec 16;14(12):2811. doi: 10.3390/v14122811. PMID: 36560815;
PMCID: PMC9781483.
2: Pires SM,
Fischer-Walker CL, Lanata CF, Devleesschauwer B, Hall AJ, Kirk MD, Duarte AS,
Black RE, Angulo FJ. Aetiology-Specific Estimates of the Global and Regional
Incidence and Mortality of Diarrhoeal Diseases Commonly Transmitted through
Food. PLoS One. 2015 Dec 3;10(12):e0142927. doi: 10.1371/journal.pone.0142927.
PMID: 26632843; PMCID: PMC4668836.
3: Robilotti E,
Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 2015 Jan;28(1):134-64.
doi: 10.1128/CMR.00075-14. PMID: 25567225; PMCID: PMC4284304.
4: Villabruna N, Koopmans MPG, de Graaf M. Animals as
Reservoir for Human Norovirus. Viruses. 2019 May 25;11(5):478. doi:
10.3390/v11050478. PMID: 31130647; PMCID: PMC6563253.
5: Karimzadeh S,
Bhopal R, Nguyen Tien H. Review of infective dose, routes of transmission and
outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory
viruses. Epidemiol Infect. 2021 Apr 14;149:e96. doi: 10.1017/S0950268821000790.
Erratum in: Epidemiol Infect. 2021 May 14;149:e116. doi:
10.1017/S0950268821001084. PMID: 33849679; PMCID: PMC8082124.
6: CDC. Norovirus
Facts and Stats. (accessed on
12/15/2024): https://www.cdc.gov/norovirus/data-research/index.html
8: Alsved M, Fraenkel
CJ, Bohgard M, Widell A, Söderlund-Strand A, Lanbeck P, Holmdahl T, Isaxon C,
Gudmundsson A, Medstrand P, Böttiger B, Löndahl J. Sources of Airborne
Norovirus in Hospital Outbreaks. Clin Infect Dis. 2020 May 6;70(10):2023-2028.
doi: 10.1093/cid/ciz584. PMID: 31257413; PMCID: PMC7201413.
9: Drossinos Y, Weber
TP, Stilianakis NI. Droplets and aerosols: An artificial dichotomy in
respiratory virus transmission. Health Sci Rep. 2021 May 7;4(2):e275. doi:
10.1002/hsr2.275. PMID: 33977157; PMCID: PMC8103093.
10: Martinson ML,
Lapham J. Prevalence of Immunosuppression Among US Adults. JAMA. 2024 Mar
12;331(10):880-882. doi: 10.1001/jama.2023.28019. PMID: 38358771; PMCID:
PMC10870224.
11: Benavidez GA,
Zahnd WE, Hung P, Eberth JM. Chronic Disease Prevalence in the US:
Sociodemographic and Geographic Variations by Zip Code Tabulation Area. Prev
Chronic Dis 2024;21:230267. DOI: http://dx.doi.org/10.5888/pcd21.230267
12: Fukuta Y, Muder
RR. Infections in psychiatric facilities, with an emphasis on outbreaks. Infect
Control Hosp Epidemiol. 2013 Jan;34(1):80-8. doi: 10.1086/668774. Epub 2012 Nov
27. PMID: 23221197.
13: Tseng CY, Chen CH, Su SC, Wu FT, Chen CC, Hsieh GY, Hung
CH, Fung CP. Characteristics of norovirus gastroenteritis outbreaks in a
psychiatric centre. Epidemiol Infect. 2011 Feb;139(2):275-85. doi:
10.1017/S0950268810000634. Epub 2010 Mar 25. PMID: 20334730.
14: Tseng CY, Chen
CH, Su SC, Wu FT, Chen CC, Hsieh GY, Hung CH, Fung CP. Characteristics of
norovirus gastroenteritis outbreaks in a psychiatric centre. Epidemiol Infect.
2011 Feb;139(2):275-85. doi: 10.1017/S0950268810000634. Epub 2010 Mar 25. PMID:
20334730.
15: Gupta SS, Bharati
K, Sur D, Khera A, Ganguly NK, Nair GB. Why is the oral cholera vaccine not
considered an option for prevention of cholera in India? Analysis of possible
reasons. Indian J Med Res. 2016 May;143(5):545-51. doi:
10.4103/0971-5916.187102. PMID: 27487997; PMCID: PMC4989827.
16: Benenson AS (ed). Control of communicable diseases in man – 12th
Edition. American Public Health Association. Washington, DC. 1975:
96-101, 125-129.